Special Issue "Assessing Novel Tobacco Products"

A special issue of Toxics (ISSN 2305-6304). This special issue belongs to the section "Toxicology".

Deadline for manuscript submissions: 10 October 2022 | Viewed by 697

Special Issue Editor

Dr. Kenneth M. Taylor *
E-Mail Website
Guest Editor
US FDA, Ctr Tobacco Prod, 10903 New Hampshire Ave, Silver Spring, MD 20993, USA
Interests: menthol; flavors; cigars; smokeless tobacco; harmful and potentially harmful constituents
* Disclaimer: The views expressed are those of the author and do not necessarily represent the official position of the U.S. Department of Health and Human Services or any of its affiliated institutions or agencies.

Special Issue Information

Dear Colleagues,

Tobacco use remains a leading cause of preventable disease, disability, and death. In May 2020, the World Health Organization (WHO) reported that tobacco use was responsible for greater than 8 million annual deaths globally. The WHO has also maintained that heated tobacco products (HTPs) and electronic nicotine delivery systems (ENDS) contain harmful constituents and that there is insufficient evidence on the long-term health effects of these novel tobacco products. Additionally, the WHO states that “there is inadequate evidence to support whether they pose less risk to cause disease compared to combusted tobacco products or the effectiveness of tobacco products like ENDS as smoking cessation aids”.

The 2018 United States National Academies of Sciences, Engineering, and Medicine report, “The Public Health Consequences of E-cigarettes”, found substantial evidence that use of ENDS leads to dependence; however, there is only moderate evidence that the risk and severity of dependence are lower for ENDS than for combusted tobacco cigarettes. Additionally, moderate evidence suggests that product characteristics such as nicotine concentration, flavoring, device type, and brand may affect users developing dependence on ENDS. Although emerging tobacco products such as ENDS, HTPs or other oral smokeless tobacco (e.g., nicotine pouches and some dissolvables) may be posited to be less harmful alternatives to conventional tobacco products, there is less evidence regarding their toxicity and long-term harm as compared to the known effects of traditional tobacco products.

This Toxics Special Issue welcomes research that aims to characterize and understand novel tobacco products along with their related health effects. Research studying the general use of flavors in tobacco products is also of interest. This Special Issue aims to add to the science that will inform tobacco control policy and regulatory actions on emerging tobacco products such as ENDS, HTPs, and novel smokeless tobacco products.

In this Special Issue, all original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

1) Chemical and toxic constituents in electronic nicotine delivery systems (ENDS), heated tobacco products (HTPs), and novel smokeless products such as nicotine pouches;

2) Identities, quantities, and origins of the chemical constituents and toxic compounds, including related degradant byproducts, in ENDS and HTP aerosol;

3) Chronic toxicity of flavor ingredients and their related thermal byproducts used in tobacco products with emphasis on exposure from inhalation;

4) Novel regimen development for measuring constituents in smoke and aerosols;

5) Effect of operating temperature on composition of aerosol from ENDS and HTPs;

6) Method development and examination of nicotine exposure from different smokeless tobacco products, including nicotine pouches;

7) Examination of the effects of product design differences and how they impact exposure to constituents and toxicity in tobacco products;

8) Biomarkers of exposure or harm in ENDS, HTPs, and novel smokeless tobacco products;

9) Perception studies of adults and youth that examine whether novel tobacco products are likely to lead to interest in, initiation of, or dual/poly use of tobacco products.

I look forward to receiving your contributions.

Dr. Kenneth M. Taylor
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Toxics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • electronic nicotine delivery systems
  • heated tobacco products
  • flavor
  • nicotine
  • biomarkers
  • tobacco constituents
  • aerosol

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


“It’s Like Jogging Next to the Highway”: A Qualitative Analysis of the Motivations and Experiences of Single-, Dual-, and Ex-Users of IQOS in The Netherlands
Toxics 2022, 10(6), 283; https://doi.org/10.3390/toxics10060283 - 26 May 2022
Viewed by 423
The popularity of heated tobacco products (HTPs) is of concern, as most users are dual users exposed to emissions of both HTPs and conventional cigarettes. Furthermore, HTPs may appeal to young people and non-smokers. This study aims to build intelligence on user experiences [...] Read more.
The popularity of heated tobacco products (HTPs) is of concern, as most users are dual users exposed to emissions of both HTPs and conventional cigarettes. Furthermore, HTPs may appeal to young people and non-smokers. This study aims to build intelligence on user experiences in order to inform policy development. We conducted five semi-structured focus group interviews with single-, dual-, and ex-users of the HTP IQOS. The discussions focused on initiation and use, experiences and perception, and knowledge and information needs. We performed a thematic analysis of the transcripts. All users smoked cigarettes and/or roll your own (RYO) tobacco before using HTP. We found that almost all users started using IQOS after being introduced to it by others. Single users successfully quit smoking cigarettes using the IQOS, liked the taste, and experienced physical benefits. Dual users experienced more satisfaction from smoking cigarettes and used the IQOS for specific occasions, such as social situations or in places with smoking bans. All IQOS users described themselves as smokers and considered using the IQOS as an alternative way of smoking. Regulators may consider providing reliable and easily accessible information and regulating points of sale, promotional activities, and product properties such as flavors and devices in order to reduce product attractiveness and discourage use. Full article
(This article belongs to the Special Issue Assessing Novel Tobacco Products)
Back to TopTop